Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 319264. Отображено 100.
16-11-1998 дата публикации

ИНСУЛИНСОДЕРЖАЩИЙ ПРЕПАРАТ (ВАРИАНТЫ)

Номер: RU0000008254U1

1. Инсулинсодержащий препарат для перорального применения на основе смеси инсулина с защитными веществами, отличающийся тем, что он выполнен в виде таблетки, сформированной из микрогранул, имеющих оболочку из материала, способствующего проникновению инсулина в ткани организма, внутри которой размещена смесь инсулина с физиологически приемлемым водорастворимым порошком. 2. Препарат по п.1, отличающийся тем, что оболочка микрогранулы выполнена из фосфолипидов. 3. Препарат по п.1, отличающийся тем, что оболочка микрогранулы выполнена из смеси фосфолипидов с антиокислителем и альфатокоферолом. 4. Препарат по п.1 - 3, отличающийся тем, что микрогранула в качестве водорастворимого порошка содержит сахара и полисахариды. 5. Инсулинсодержащий препарат на основе смеси инсулина с защитными веществами, отличающийся тем, что он выполнен в виде порошка из микрогранул, имеющих оболочку из материала, способствующего проникновению инсулина в ткани организма, внутри которой размещена смесь инсулина с физиологически приемлемым водорастворимым порошком. 6. Препарат по п.5, отличающийся тем, что оболочка микрогранулы выполнена из фосфолипидов. 7. Препарат по п.5, отличающийся тем, что оболочка микрогранулы выполнена из смеси фосфолипидов с антиокислителем и альфа-токоферолом. 8. Препарат по пп. 5 - 7, отличающийся тем, что микрогранула в качестве водорастворимого порошка содержит сахара и полисахариды. (19) RU (11) (13) 8 254 U1 (51) МПК A61K 9/14 (1995.01) A61K 38/28 (1995.01) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К СВИДЕТЕЛЬСТВУ (21), (22) Заявка: 98102220/20, 12.02.1998 (46) Опубликовано: 16.11.1998 (71) Заявитель(и): Автушенко Сергей Сергеевич (72) Автор(ы): Автушенко Сергей Сергеевич R U (73) Патентообладатель(и): Автушенко Сергей Сергеевич Ñòðàíèöà: 1 8 2 5 4 R U U 1 (57) Формула полезной модели 1. Инсулинсодержащий препарат для перорального применения на основе смеси инсулина с защитными веществами, отличающийся тем, что он выполнен в ...

Подробнее
10-03-2001 дата публикации

ИНТЕРФЕРОНСОДЕРЖАЩИЙ ПРЕПАРАТ

Номер: RU0000016999U1

1. Интерферонсодержащий препарат в виде микрокапсулы, состоящий из оболочки и размещенного в ней активного начала на основе интерферона, отличающийся тем, что оболочка выполнена из материала, содержащего ионы серебра и не менее двух поверхностно-активных веществ различного молекулярного веса. 2. Интерферонсодержащий препарат по п.1, отличающийся тем, что он выполнен в виде микрокапсул размером 5-50 нм. 3. Интерферонсодержащий препарат по п.1, отличающийся тем, что в состав оболочки входят неионогенные поверхностно-активные вещества. (19) RU (11) 16 999 (13) U1 (51) МПК A61K 9/00 (2000.01) A61K 38/21 (2000.01) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К СВИДЕТЕЛЬСТВУ (21), (22) Заявка: 2000126638/20 , 25.10.2000 (24) Дата начала отсчета срока действия патента: 25.10.2000 (46) Опубликовано: 10.03.2001 (73) Патентообладатель(и): Государственный научно-исследовательский институт особо чистых биопрепаратов U 1 1 6 9 9 9 R U (57) Формула полезной модели 1. Интерферонсодержащий препарат в виде микрокапсулы, состоящий из оболочки и размещенного в ней активного начала на основе интерферона, отличающийся тем, что оболочка выполнена из материала, содержащего ионы серебра и не менее двух поверхностно-активных веществ различного молекулярного веса. 2. Интерферонсодержащий препарат по п.1, отличающийся тем, что он выполнен в виде микрокапсул размером 5-50 нм. 3. Интерферонсодержащий препарат по п.1, отличающийся тем, что в состав оболочки входят неионогенные поверхностно-активные вещества. Ñòðàíèöà: 1 U 1 (54) ИНТЕРФЕРОНСОДЕРЖАЩИЙ ПРЕПАРАТ 1 6 9 9 9 (72) Автор(ы): Николаев Б.П., Свентицкий Е.Н., Шляков А.М., Яковлева Л.Ю., Черняева Е.В., Торопов Д.К., Тяготин Ю.В., Родин С.В., Симбирцев А.С. R U Адрес для переписки: 193318, Санкт-Петербург, ул.Подвойского 14, корп.1, кв.741, Кузнецову В.А. (71) Заявитель(и): Государственный научно-исследовательский институт особо чистых биопрепаратов U 1 U 1 1 6 9 9 9 1 6 9 9 9 R U R U Ñòðàíèöà: 2 RU 16 999 ...

Подробнее
05-01-2012 дата публикации

Dendrimer based nanodevices for therapeutic and imaging purposes

Номер: US20120003155A1

A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.

Подробнее
05-01-2012 дата публикации

Methods and compositions for modulating proline levels

Номер: US20120003207A1
Автор: Mike A. Clark
Принадлежит: ONCOPHARMACOLOGICS Inc

Methods and compositions for modulating amino acid levels in a subject are provided herein.

Подробнее
05-01-2012 дата публикации

Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy

Номер: US20120003229A1
Принадлежит: Individual

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Подробнее
05-01-2012 дата публикации

Recombinant avian infectious coryza vaccine and process for preparing same

Номер: US20120003257A1

A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and colleting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.

Подробнее
05-01-2012 дата публикации

Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss

Номер: US20120003300A1
Принадлежит: Pangaea Laboratories Ltd

A composition to treat hair loss and enhance hair growth and condition. The composition comprises: i) one or more of VEGF, a VEGF biomimetic peptide, and/or a VEGFR2 receptor agonist; ii) ciclopirox olamine; and iii) a pharmaceutically acceptable carrier.

Подробнее
05-01-2012 дата публикации

Homogenous preparations of il-28 and il-29

Номер: US20120004161A1
Принадлежит: Zymogenetics Inc

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Подробнее
05-01-2012 дата публикации

Formulation Comprising Bioactive Agents And Method Of Using Same

Номер: US20120004170A1

Disclosed are methods of making bioactive BMP-2 microparticles and methods of using the microparticles.

Подробнее
05-01-2012 дата публикации

Method of treatment or prophylaxis

Номер: US20120004259A1
Принадлежит: SPINIFEX PHARMACEUTICALS PTY LTD

The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT 2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT 2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.

Подробнее
05-01-2012 дата публикации

Compounds for the treatment of pathologies associated with aging and degenerative disorders

Номер: US20120004263A1
Принадлежит: University of Pittsburgh

The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Подробнее
05-01-2012 дата публикации

Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia

Номер: US20120004395A1
Принадлежит: MED DISCOVERY SA, Universitaet Zuerich

The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Подробнее
05-01-2012 дата публикации

Apparatus and methods for enzymatic debridement of skin lesions

Номер: US20120004627A1

An apparatus for debridement of devitalized tissue in skin lesions, that includes a plurality of height- and angle-adjustable inlet tubes and at least one outlet tube and a member that forms an occlusive seal around a skin lesion. The plurality of inlet tubes is adapted for directing a continuous stream of enzymatic solution to the surface and into the entire volume of the wound bed of the lesion and the at least one outlet is adapted for removing the enzymatic solution, fluids draining from the lesion and tissue debris from the occluded skin lesion.

Подробнее
10-04-2016 дата публикации

УСТРОЙСТВО ДЛЯ ПРИГОТОВЛЕНИЯ КОМПОНЕНТОВ БИОЛОГИЧЕСКОГО КЛЕЯ

Номер: RU0000161127U1

Устройство для приготовления компонентов биологического клея, содержащее устройство для получения тромбина и емкость для тромбина, устройство для получения свертывающихся и адгезивных белков, магистраль системы приема жидкости, соединенную с каждым из указанных устройств, блок контейнеров с размещением в каждом контейнере шприца для тромбина и шприца для свертывающихся и адгезивных белков, при этом блок контейнеров непосредственно соединен при помощи магистрали с устройством для получения свертывающихся и адгезивных белков, а емкость для тромбина выполнена в виде ромбообразного пластикового пакета и соединена магистралями с устройством для получения тромбина и с блоком контейнеров. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61K 38/48 (13) 161 127 U1 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ 2015103353/15, 27.01.2015 (24) Дата начала отсчета срока действия патента: 27.01.2015 (73) Патентообладатель(и): Общество с ограниченной ответственностью "Центр инновационных разработок Вирави" (ООО "Вирави") (RU) (45) Опубликовано: 10.04.2016 Бюл. № 10 1 6 1 1 2 7 R U Формула полезной модели Устройство для приготовления компонентов биологического клея, содержащее устройство для получения тромбина и емкость для тромбина, устройство для получения свертывающихся и адгезивных белков, магистраль системы приема жидкости, соединенную с каждым из указанных устройств, блок контейнеров с размещением в каждом контейнере шприца для тромбина и шприца для свертывающихся и адгезивных белков, при этом блок контейнеров непосредственно соединен при помощи магистрали с устройством для получения свертывающихся и адгезивных белков, а емкость для тромбина выполнена в виде ромбообразного пластикового пакета и соединена магистралями с устройством для получения тромбина и с блоком контейнеров. Стр.: 1 U 1 U 1 (54) УСТРОЙСТВО ДЛЯ ПРИГОТОВЛЕНИЯ КОМПОНЕНТОВ БИОЛОГИЧЕСКОГО КЛЕЯ 1 6 1 1 2 7 Адрес для переписки: 620086, ...

Подробнее
21-02-2017 дата публикации

Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях

Номер: RU0000168865U1

Полезная модель относится к медицине, а именно к устройствам, применяемым в медицине катастроф. Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях предназначено для оказания первой помощи в очаге катастрофы, а также для временной остановки наружного кровотечения при транспортировке пострадавшего. Авторы предлагают салфетку из гемостатических коллагеновых пластин в сочетании с антибактериальными и кровоостанавливающими препаратами, при этом оно состоит не менее чем из двух гемостатических коллагеновых пластин толщиной не менее 3 мм, при этом нижняя пластина покрыта смесью порошков цеолита и сульфаниламида в равных пропорциях толщиной не менее 1 мм, а верхняя пластина пропитана гентамицином из расчета 40 мг на 1 см пластины, салфетки могут быть упакованы в стерильную оболочку. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 168 865 U1 (51) МПК A61L 15/32 (2006.01) A61L 15/44 (2006.01) A61K 31/7036 (2006.01) A61K 31/63 (2006.01) A61K 33/06 (2006.01) A61K 38/39 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА A61P 7/04 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ A61P 31/04 (2006.01) (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21)(22) Заявка: 2016131818, 03.08.2016 (24) Дата начала отсчета срока действия патента: 03.08.2016 (73) Патентообладатель(и): Рыбакова Маргарита Викторовна (RU) Дата регистрации: (56) Список документов, цитированных в отчете о поиске: SU 1705304 A1, 15.01.2002. US Приоритет(ы): (22) Дата подачи заявки: 03.08.2016 (45) Опубликовано: 21.02.2017 Бюл. № 6 U 1 R U Стр.: 1 U 1 (54) Устройство с антибактериальными и кровоостанавливающими свойствами для оказания первой помощи при ранениях (57) Реферат: Полезная модель относится к медицине, а антибактериальными и кровоостанавливающими именно к устройствам, применяемым в медицине препаратами, при этом оно состоит не менее чем катастроф. Устройство с антибактериальными и из двух гемостатических коллагеновых пластин кровоостанавливающими свойствами для толщиной не менее 3 мм, при этом ...

Подробнее
31-01-2018 дата публикации

КРОВООСТАНАВЛИВАЮЩИЙ ПАКЕТ

Номер: RU0000176884U1

Полезная модель относится к области медицины, а именно к индивидуальным местным гемостатическим средствам, предназначенным для оказания первой само- и взаимопомощи при ранениях и травмах. Техническое решение направлено на создание устройства для обеспечения возможности местного воздействия на раны и поврежденные сосуды с использованием гемостатического средства, полученного путем формования растворов хитозана и его солей в композиции с добавками, для снижения времени наступления гемостаза и повышения антимикробной и противошоковой активности в сочетании с перевязочными средствами. Технический результат заявленного изобретения достигается тем, что предложен кровоостанавливающий пакет, содержащий упаковку, перевязочный комплект, включающий абсорбирующую подушечку, бинт из эластично-трикотажного материала, фиксирующий элемент, отличающийся тем, что абсорбирующая подушечка выполнена в виде сложенной гармошкой ленты, изготовленной из нетканого полотна, полученного путем электроформования растворов хитозана или соли хитозана с последующим нанесением на нее ворса из биополимерных нановолокон, полученных путем электроформования растворов хитозана или соли хитозана с антимикробными, обезболивающими веществами. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 176 884 U1 (51) МПК A61L 15/00 (2006.01) A61F 13/00 (2006.01) A61K 38/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК A61L 15/00 (2006.01); A61F 13/00 (2006.01); A61K 38/00 (2006.01) (21)(22) Заявка: 2017133325, 25.09.2017 (24) Дата начала отсчета срока действия патента: Дата регистрации: 31.01.2018 (45) Опубликовано: 31.01.2018 Бюл. № 4 1 7 6 8 8 4 R U (54) КРОВООСТАНАВЛИВАЮЩИЙ ПАКЕТ (57) Реферат: Полезная модель относится к области медицины, а именно к индивидуальным местным гемостатическим средствам, предназначенным для оказания первой само- и взаимопомощи при ранениях и травмах. Техническое решение направлено на создание устройства для обеспечения возможности ...

Подробнее
12-01-2012 дата публикации

Modified Fc Molecules

Номер: US20120009205A1
Принадлежит: AMGEN INC

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Подробнее
12-01-2012 дата публикации

Novel cyclosporin analogues

Номер: US20120010131A1
Принадлежит: Scynexis Chemistry and Automation Inc

The invention relates to the use of cyclic compounds of general formula (I): wherein A, B, R 1 and R 2 are as defined in the specification, and their use as pharmaceuticals.

Подробнее
12-01-2012 дата публикации

Novel uses of vegfxxxb

Номер: US20120010138A1
Принадлежит: University of Bristol

The invention provides VEGF xxx b, or an agent which selectively promotes the expression of VEGF xxx b in preference to VEGF xxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGF xxx b in a host organism, for use in treating or preventing microvascular hyperpermeability disorders, or in regulating the pro-angiogenic pro-permeability properties of VEGF xxx isoforms, or in supporting epithelial cell survival without increased permeability, or in reducing the nature (for example the number density and/or size) of fenestrations of epithelial filtration membranes in vivo or in vitro.

Подробнее
12-01-2012 дата публикации

Self-assembling peptides for regeneration and repair of neural tissue

Номер: US20120010140A1
Принадлежит: Massachusetts Institute of Technology

The present invention provides methods and compositions for enhancing regeneration and/or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a location on one side of a site of injury or barrier to a location on the other side of the site of injury or barrier. A second method includes introducing a composition comprising self-assembling peptides into the subject at the site of injury, wherein the peptides are amphiphilic peptides that comprise substantially equal proportions of hydrophobic and hydrophilic amino acids and are complementary and structurally compatible. A variety of compositions comprising a nanoscale structured material or precursor thereof, and an additional substance such as a regeneration promoting factor, are also provided. In certain embodiments of the invention the nanoscale structured material or precursor thereof comprises self-assembling peptides. The invention further provides compositions and methods for repair of an intervertebral disc, including nucleus pulpusos repair.

Подробнее
12-01-2012 дата публикации

Natriuretic activities

Номер: US20120010142A1

This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.

Подробнее
12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1
Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее
12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1
Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее
12-01-2012 дата публикации

Composition comprising various proteorhodopsins and/or bacteriorhodopsins and use thereof

Номер: US20120010333A1
Принадлежит: DANISCO US INC, Genencor International Inc

The present invention provides a solid material comprising an immobilized mixture of two or more proteorhodopsins, two or more bacteriorhodopsins, or one or more bacteriorhodopsin and one or more proteorhodopsins. The proteorhodopsins are selected from the group consisting of all-trans-retinal-containing proteorhodopsins and retinal analog-containing proteorhodopsins; all of which have absorption spectra that do not overlap. The bacteriorhodopsins are selected from the group consisting of all-trans-retinal-containing bacteriorhodopsins and retinal analog-containing bacteriorhodopsins; all of which have absorption spectra that do not overlap. The present invention also provides an optical information carrier, such as an optical data storage material and a fraud-proof optical data carrier, comprising the above-described solid material and a substrate selected from the group consisting of glass, paper, metal, fabric material, and plastic material, wherein said solid material is deposited on said substrate. The present invention further provides security ink comprising one or more hydrophilic polymers and a mixture of various photochromic materials.

Подробнее
19-01-2012 дата публикации

Soothing cosmetic or pharmaceutical composition comprising a peptide which activates hmg-coa reductase

Номер: US20120014886A1
Принадлежит: ISP Investments LLC

The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R 1 -(AA) n -X 1 -Gly-Lys-X 2 -(AA) p -R 2 and sequence SEQ ID No. 1 to SEQ ID No. 10, in a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.

Подробнее
19-01-2012 дата публикации

Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders

Номер: US20120014915A9
Автор: Rhonda Voskuhl
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post

Подробнее
19-01-2012 дата публикации

Methods and compositions for cns delivery of heparan n-sulfatase

Номер: US20120014936A1
Принадлежит: Shire Human Genetics Therapies Inc

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Подробнее
19-01-2012 дата публикации

Compositions with reduced dimer formation

Номер: US20120014978A1
Принадлежит: Circassia Ltd

The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Подробнее
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
19-01-2012 дата публикации

Kallikrein-inhibitor therapies

Номер: US20120015881A1
Принадлежит: Dyax Corp

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Подробнее
19-01-2012 дата публикации

Mek mutations conferring resistance to mek inhibitors

Номер: US20120015973A1

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

Подробнее
19-01-2012 дата публикации

Growth factor htter36

Номер: US20120016107A1
Принадлежит: Human Genome Sciences Inc

The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided are antibodies that bind HTTER36, including chimeric, humanized, and single chain antibodies.

Подробнее
19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1
Автор: Zhao Yi Wang
Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее
26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1
Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее
26-01-2012 дата публикации

Leukemia inhibitory factor (lif) for use in repressing human papillomavirus (hpv) transcription

Номер: US20120020914A1
Принадлежит: Leland Stanford Junior University

Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF.

Подробнее
26-01-2012 дата публикации

Methods for accelerating wound healing by administration of adipokines

Номер: US20120020917A1
Принадлежит: Individual

Methods for inducing or accelerating a healing process of a damaged skill or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound.

Подробнее
26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1
Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее
26-01-2012 дата публикации

METHODS FOR TREATING IgE-MEDIATED DISORDER

Номер: US20120020979A1
Автор: Andrea Cerutti, KANG Chen
Принадлежит: CORNELL UNIVERSITY

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Подробнее
26-01-2012 дата публикации

Process for making dry and stable hemostatic compositions

Номер: US20120021058A1
Автор: Andreas Goessl

Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a dry granular preparation of a biocompatible polymer suitable for use in hemostasis, b) coating the granules in said dry granular preparation with a preparation of a coagulation inducing agent, thereby obtaining coagulation inducing agent coated polymer granules, c) filling said coagulation inducing agent coated polymer granules into a final container, d) finishing the final container to a storable pharmaceutical device containing said coagulation inducing agent coated polymer granules as a dry and stable hemostatic composition.

Подробнее
26-01-2012 дата публикации

Use of a synergistic combination of hypothiocyanite and/or hypohalite ions and lactoferrin for preparing a treatment for cystic fibrosis

Номер: US20120021071A1
Принадлежит: ALAXIA SAS

The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.

Подробнее
26-01-2012 дата публикации

Methods for magnetic resonance imaging

Номер: US20120021450A1
Принадлежит: CARNEGIE MELLON UNIVERSITY

In certain aspects the present invention provides methods and compositions related to contrast agents for magnetic resonance imaging. In certain variations, contrast agents provided herein are generated in situ via genetic instructions and become potent upon sequestering available metal atoms. Exemplary contrast agents include metal-binding proteins.

Подробнее
26-01-2012 дата публикации

Antibiotic peptides

Номер: US20120021975A1
Принадлежит: AMP Therapeutics GmbH and Co KG

The invention relates to a peptide or peptide derivative having the general formula: Sub 1 -X 1 -D 2 K 3 -P 4 -P 5 -Y 6 -L 7 -P 8 -R 9 -P 10 -X 2 -P 12 -P 13 -R 14 -X 3 -I 16 -P 17 /Y 17 -N 18 -N 19 -X 4 -Sub 2 , wherein X 1 is a non-polar, hydrophobic group or a positively charged group, D 2 is asparagine or glutamine, K 3 , X 2 , and X 4 are positively charged groups, X 3 is a positively charged group, proline, or a proline derivative; L 7 and I 16 are non-polar, hydrophobic groups, Y 6 and Y 17 are tyrosine, R 9 and R 14 are arginine, N 18 and N 19 are asparagine or glutamine, P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , and P 17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D 2 , P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , P 17 , and Y 17 are replaced by an arbitrary group and/or P 13 and R 14 are exchanged, Sub 1 is the free or modified N-terminus, and Sub 2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.

Подробнее
26-01-2012 дата публикации

Combination of an insulin and a glp-1-agonist

Номер: US20120021978A1
Принадлежит: Sanofi Aventis Deutschland GmbH

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Подробнее
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
26-01-2012 дата публикации

Recombinant Anti-VLA4 Antibody Molecules

Номер: US20120022236A1
Принадлежит: BIOGEN IDEC MA INC

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Подробнее
26-01-2012 дата публикации

Compositions and Methods for Induced Brown Fat Differentiation

Номер: US20120022500A1
Принадлежит: Dana Farber Cancer Institute Inc

The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of both Prdm1β and C/EBPβ activity and/or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of both Prdm1β and C/EBPβ expression and/or activity. Further provided are methods for identifying compounds that are capable of modulating both Prdm1β and C/EBPβ expression and/or activity.

Подробнее
02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее
02-02-2012 дата публикации

Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis

Номер: US20120027718A1
Принадлежит: Teva Pharmaceutical Industries LTD

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.

Подробнее
02-02-2012 дата публикации

Thermoreversible collagen

Номер: US20120027732A1
Принадлежит: PURDUE RESEARCH FOUNDATION

This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation.

Подробнее
02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1
Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее
02-02-2012 дата публикации

Modified heparinase iii and methods of sequencing therewith

Номер: US20120027744A1
Принадлежит: Massachusetts Institute of Technology

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Подробнее
02-02-2012 дата публикации

Highly sensitive detection method for highly virulent oral cavity bacteria

Номер: US20120028879A1

Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method.

Подробнее
02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1
Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее
02-02-2012 дата публикации

Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A

Номер: US20120028905A1

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.

Подробнее
02-02-2012 дата публикации

Storage-stable aqueous ophthalmic formulations

Номер: US20120028910A1
Принадлежит: Fovea Pharmaceuticals SA

Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

Подробнее
02-02-2012 дата публикации

Methods and compositions comprising tau oligomers

Номер: US20120029169A1
Принадлежит: Oligomerix Inc

Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught.

Подробнее
02-02-2012 дата публикации

Posterior segment drug delivery

Номер: US20120029470A1
Принадлежит: ForSight Vision4 Inc

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Подробнее
09-02-2012 дата публикации

Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer

Номер: US20120034167A1

The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.

Подробнее
09-02-2012 дата публикации

Extracellular matrix compositions for tissue regeneration

Номер: US20120034191A1
Автор: Robert G. Matheny
Принадлежит: Individual

The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.

Подробнее
09-02-2012 дата публикации

Compositions for potentiating apoposis signals in tumour cells

Номер: US20120034210A1

The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.

Подробнее
09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее
09-02-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity

Номер: US20120034251A1
Принадлежит: Momotaro Gene Inc

According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.

Подробнее
09-02-2012 дата публикации

Compositions for the treatment of gluten intolerance and uses thereof

Номер: US20120034299A1
Принадлежит: Glutagen Pty Ltd

The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.

Подробнее
09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1
Автор: Dirk M. Anderson
Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее
09-02-2012 дата публикации

Neuronal differentiation-inducing peptide and use thereof

Номер: US20120035112A1
Принадлежит: TOAGOSEI CO LTD

A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.

Подробнее
16-02-2012 дата публикации

Lateral Flow Assays for Non-Diagnostic Analytes

Номер: US20120040336A1
Принадлежит: Clontech Laboratories Inc

Methods of determining whether a non-diagnostic analyte is present in a non-diagnostic sample are provided. Aspects of the methods include applying a non-diagnostic sample to a sample receiving region of a lateral flow assay device and reading a detection region to determine whether a non-diagnostic analyte is present in the non-diagnostic sample. Also provided are kits that find use in practicing methods of the invention.

Подробнее
16-02-2012 дата публикации

Methods and materials for delivering molecules

Номер: US20120040432A1

This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.

Подробнее
16-02-2012 дата публикации

Mini-Hepcidin Peptides and Methods of Using thereof

Номер: US20120040894A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Подробнее
16-02-2012 дата публикации

Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes

Номер: US20120040909A1

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Подробнее
16-02-2012 дата публикации

Method for the manufacture of degarelix

Номер: US20120041172A1
Принадлежит: PolyPeptide Laboratories AS

In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH 2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH 2 ; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

Подробнее
16-02-2012 дата публикации

Ucp4

Номер: US20120041176A1
Принадлежит: Genentech Inc

The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.

Подробнее
23-02-2012 дата публикации

Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF

Номер: US20120042613A1
Принадлежит: SANDOZ AG

The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Подробнее
23-02-2012 дата публикации

Composition and Methods for the Diagnosis and Treatment of Tumor

Номер: US20120045390A1
Принадлежит: Genentech Inc

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Подробнее
23-02-2012 дата публикации

Lhrh-ii peptide analogs

Номер: US20120045393A1
Принадлежит: BRACCO IMAGING SPA

The invention is directed to analogs of LHRH-II and, more generally, to analogs of the LHRH family in which modifications have been made that confer enhanced binding affinity for LHRH receptors and/or improved metabolic stability. The invention is further directed to methods of targeted therapy and targeted imaging in patients with sex-hormone-related cancers or other LHRH-mediated diseases.

Подробнее
23-02-2012 дата публикации

Human papilloma virus peptide-specific T-cell response for treatment of warts

Номер: US20120045413A1
Принадлежит: Kevin Kim, Mayumi Nakagawa, Thomas Horn

The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) found in and causing the warts. It was found that the patients showed a response to HPV type 57 L1 peptide 380-412 (a peptide consisting of amino acid residues 380-412 of the protein L1) and HPV type 57 protein E4 (E4 10-30). One embodiment of the invention provides a pharmaceutical composition comprising a polypeptide comprising (a) L1 380-412 (SEQ ID NO:3) or a fragment of at least 8 residues of SEQ ID NO:3 or (b) E4 10-30 (SEQ ID NO:4) or a fragment of at least 8 residues of E4 10-30 (SEQ ID NO:4), wherein the composition is immunogenic in humans.

Подробнее
23-02-2012 дата публикации

Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof

Номер: US20120045464A1
Автор: J. Neil Simonsen
Принадлежит: Individual

Cloning and expression of genes encoding C. parvum antigenic polypeptides are described as are antibodies that recognize epitopes on these polypeptides. The antigenic polypeptides and antibodies thereto can be used in therapeutic compositions for the prevention and treatment of C. parvum infections, as well as in diagnostic methods for determining the presence of C. parvum infections.

Подробнее
23-02-2012 дата публикации

Substrate peptide sequences for plague plasminogen activator and uses thereof

Номер: US20120045474A1
Принадлежит: Individual

The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis . Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.

Подробнее
23-02-2012 дата публикации

TNF-alpha Antagonists Containing IGFBP5

Номер: US20120046217A1

The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Подробнее
23-02-2012 дата публикации

Glutathione-based delivery system

Номер: US20120046445A1
Принадлежит: Individual

A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.

Подробнее
23-02-2012 дата публикации

Coating Comprising An Elastin-Based Copolymer

Номер: US20120046640A1
Принадлежит: Abbott Cardiovascular Systems Inc

The present invention is directed to medical devices including coatings. The coatings include a topcoat which includes a copolymer comprising a block of an elastin pentapeptide. The topcoat is over a layer of poly(vinyl alcohol) on a hydrophobic coating or over a porous coating comprising pores or depots that include a bioactive agent.

Подробнее
23-02-2012 дата публикации

Devices and methods for treating defects in the tissue of a living being

Номер: US20120046758A1

An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery.

Подробнее
01-03-2012 дата публикации

Microorganisms for preventing and treating neoplasms accompanying cellular therapy

Номер: US20120052003A9
Автор: Aladar A. Szalay
Принадлежит: Genelux Corp

Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of neoplastic cells prior to administration of the cellular composition for therapy. Diagnostic methods for monitoring treatment also are provided.

Подробнее
01-03-2012 дата публикации

Methods of managing the blood coagulation and pharmaceutical compositions related thereto

Номер: US20120052058A1
Принадлежит: EMORY UNIVERSITY

The disclosure relates to methods of managing blood coagulation and pharmaceutical compositions related thereto. In certain embodiments, the disclosure relates to methods of managing the coagulation of blood in a patient undergoing surgery comprising administering combinations of a direct thrombin inhibitor and a coagulation factor inhibitor. In some embodiments, the disclosure relates to treating or preventing clotting by administering compositions disclosed herein to a subject at risk for, exhibiting symptoms of, or diagnosed with a blood clot.

Подробнее
01-03-2012 дата публикации

Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Номер: US20120052097A1
Принадлежит: Cerulean Pharma Inc

Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles.

Подробнее
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
01-03-2012 дата публикации

Splice-region antisense composition and method

Номер: US20120053228A1
Принадлежит: AVI Biopharma Inc

Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. Such targeting is effective to inhibit natural mRNA splice processing, produce splice variant mRNAs, and inhibit normal expression of the protein.

Подробнее
08-03-2012 дата публикации

method for promoting bone growth using activin-actriia antagonists

Номер: US20120058115A1
Автор: Jasbir Seehra, John Knopf
Принадлежит: Acceleron Pharma Inc

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.

Подробнее
08-03-2012 дата публикации

Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin

Номер: US20120058199A1
Принадлежит: BASF SE

The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.

Подробнее
08-03-2012 дата публикации

Compositions and methods for elimination of gram negative bacteria

Номер: US20120058936A1

Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.

Подробнее
08-03-2012 дата публикации

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Номер: US20120058945A1

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.

Подробнее
08-03-2012 дата публикации

Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same

Номер: US20120058952A1
Принадлежит: ISP Investments LLC

The present invention relates to a peptide of general formula (I): R 1 -(AA) n -X 1 -Gly-Glu-Leu-Ser-X 2 -X 3- (AA) p -R 2 , derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Подробнее
15-03-2012 дата публикации

Rtef-1 variants and uses thereof

Номер: US20120063994A1

Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.

Подробнее
15-03-2012 дата публикации

Delivery system with scaffolds

Номер: US20120063997A1
Принадлежит: REGENTEC Ltd

An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it can be used in tissue regeneration or reconstruction. The agent for delivery may be a therapeutically, prophylactically or diagnostically active substance.

Подробнее
15-03-2012 дата публикации

Psca: prostate stem cell antigen and uses thereof

Номер: US20120063999A1
Принадлежит: Agensys Inc, UNIVERSITY OF CALIFORNIA

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Подробнее
15-03-2012 дата публикации

Peptidomimetic protease inhibitors

Номер: US20120064034A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Подробнее
15-03-2012 дата публикации

Il-17 homologous polypeptides and therapeutic uses thereof

Номер: US20120064073A1
Принадлежит: Individual

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Подробнее
15-03-2012 дата публикации

Aminoacyl trna synthetases for modulating hematopoiesis

Номер: US20120064082A1
Принадлежит: aTyr Pharma Inc

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.

Подробнее
15-03-2012 дата публикации

Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents

Номер: US20120064532A1
Принадлежит: NOVARTIS AG

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

Подробнее
15-03-2012 дата публикации

Methods of Diagnosing Hypophosphatemic Disorders

Номер: US20120064544A1

The present invention relates to methods of diagnosing hypophosphatemic disorders.

Подробнее